CLAIM CARD
The evidence base for rapamycin's effects on immune and inflammatory outcomes spans preclinical, observational, and clinical trial designs. Observational cohort studies in adults explored rapamycin's suppression of inflammation in fatty liver models, where rapamycin stock solutions were prepared at 0.05 mg/μL concentration (Ge 2023). Additional cohort work investigated rapamycin's cardioprotective effects in autoimmune myocarditis using doses of 1 mg/kg (Zhuang 2025).
Evidence grade: exploratory
Contradiction status: none
Publication: f02d4a53-03e5-47ed-9876-75a416e3bd24
Provenance: Derivation Web chain
Citation Support
source_1Moel 2025source_2Gkioni 2025source_3Smiaek 2023source_4Willows 2023source_5Harinath 2025